Both the cytosols and detergent extracts of breast cancer tissues are suited to evaluate the prognostic impact of the urokinase-type plasminogen activator and its inhibitor, plasminogen activator inhibitor type 1
- PMID: 8168072
Both the cytosols and detergent extracts of breast cancer tissues are suited to evaluate the prognostic impact of the urokinase-type plasminogen activator and its inhibitor, plasminogen activator inhibitor type 1
Abstract
The serine protease urokinase-type plasminogen activator (uPA) plays a key role in tumor-associated proteolysis in malignant solid tumors. Proteolytic activity of uPA is controlled by its naturally occurring plasminogen activator inhibitor type 1. As an initial observation, a correlation of enzymatic uPA activity in breast cancer cytosols with prognosis was described in 1988 (Duffy et al., Cancer (Phila.), 62: 531-533, 1988). A pronounced prognostic impact of uPA, independent of classical risk parameters, was then first demonstrated in detergent-extracted (Triton X-100) breast cancer tissues by applying enzyme-linked immunosorbent assay techniques (Jänicke et al., Lancet, 2: 1049, 1989; Fibrinolysis, 4:69-78, 1990; Duffy et al., Cancer Res., 50: 6827-6829, 1990). In addition, not only uPA but also plasminogen activator inhibitor type 1 were shown to be of prognostic value in breast cancer (Jänicke et al., Semin. Thromb. Hemostasis, 17: 303-312, 1991; Breast Cancer Res. Treat., 24: 195-208, 1993). Subsequently, the prognostic value of uPA and plasminogen activator inhibitor type 1 was also confirmed in studies using archived "cytosol fractions" of breast cancer tissues (Foekens et al., Cancer Res., 52: 6101-6105, 1992; Spyratos et al., J. Natl. Cancer Inst., 84: 1266-1272, 1992; Grondahl-Hansen et al., Cancer Res., 53: 2513-2521, 1993; Sumiyoshi et al., Int. J. Cancer, 50: 345-348, 1992). A direct comparison of both methods with regard to prognosis, however, was lacking. We therefore prepared both the detergent-treated tissue extracts and the cytosol fractions from the same breast cancer specimens to allow a direct comparison of both methods. In 247 breast cancer patients investigated, the Triton X-100-extracted tissues revealed about twice as much uPA antigen (uPATx: median, 2.32 ng/mg protein) than the cytosol fractions (uPAcyt: median, 1.07 ng/mg protein). In contrast, the presence of Triton X-100 did not result in an increase of PAI-1 (PAI-1Tx: median, 6.34 ng PAI-1/mg protein) compared to the cytosol fractions (PAI-1cyt: median, 7.15 ng PAI-1/mg protein). Good correlations between uPATx and uPAcyt (R = 0.72) and between PAI-1Tx and PAI-1cyt (R = 0.88) were observed. Furthermore, PAI-1 and uPA are moderately correlated with each other (uPATx versus PAI-1Tx: R = 0.40; uPAcyt versus PAI-1cyt: R = 0.39). The prognostic power of uPA showed its best advantage in Triton X-100-extracted tissues (RR = 3.22), most pronounced in the subgroups of node-negative and premenopausal patients, respectively.(ABSTRACT TRUNCATED AT 400 WORDS)
Similar articles
-
Plasminogen activator inhibitor type 1 in cytosolic tumor extracts predicts prognosis in low-risk breast cancer patients.Clin Cancer Res. 1997 Feb;3(2):233-9. Clin Cancer Res. 1997. PMID: 9815678
-
High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis.Cancer Res. 1993 Jun 1;53(11):2513-21. Cancer Res. 1993. PMID: 8388317
-
Prognostic significance of the receptor for urokinase plasminogen activator in breast cancer.Clin Cancer Res. 1995 Oct;1(10):1079-87. Clin Cancer Res. 1995. PMID: 9815897
-
Urokinase-type plasminogen activator (uPA) and its inhibitor PAI-I: novel tumor-derived factors with a high prognostic and predictive impact in breast cancer.Thromb Haemost. 2004 Mar;91(3):450-6. doi: 10.1160/TH03-12-0798. Thromb Haemost. 2004. PMID: 14983219 Review.
-
Urokinase-type plasminogen activator system and breast cancer (Review).Oncol Rep. 2005 Jul;14(1):105-12. Oncol Rep. 2005. PMID: 15944776 Review.
Cited by
-
Biomolecular features of clinical relevance in breast cancer.Eur J Nucl Med Mol Imaging. 2004 Jun;31 Suppl 1:S3-14. doi: 10.1007/s00259-004-1522-0. Epub 2004 Apr 17. Eur J Nucl Med Mol Imaging. 2004. PMID: 15095022 Review.
-
Inverse association of rab31 and mucin-1 (CA15-3) antigen levels in estrogen receptor-positive (ER+) breast cancer tissues with clinicopathological parameters and patients' prognosis.Am J Cancer Res. 2017 Sep 1;7(9):1959-1970. eCollection 2017. Am J Cancer Res. 2017. PMID: 28979817 Free PMC article.
-
Evaluation and correlation of risk recurrence in early breast cancer assessed by Oncotype DX®, clinicopathological markers and tumor cell dissemination in the blood and bone marrow.Mol Clin Oncol. 2013 Nov;1(6):1049-1054. doi: 10.3892/mco.2013.174. Epub 2013 Sep 2. Mol Clin Oncol. 2013. PMID: 24649291 Free PMC article.
-
uPA/PAI-1 ratios distinguish benign prostatic hyperplasia and prostate cancer.J Cancer Res Clin Oncol. 2013 Jul;139(7):1221-8. doi: 10.1007/s00432-013-1428-y. Epub 2013 Apr 18. J Cancer Res Clin Oncol. 2013. PMID: 23595126 Free PMC article.
-
Identification of BRCA1-like triple-negative breast cancers by quantitative multiplex-ligation-dependent probe amplification (MLPA) analysis of BRCA1-associated chromosomal regions: a validation study.BMC Cancer. 2016 Oct 19;16(1):811. doi: 10.1186/s12885-016-2848-2. BMC Cancer. 2016. PMID: 27756336 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical
Research Materials
Miscellaneous